» Articles » PMID: 15734835

Increased Potency and Efficacy of Combined Phosphorylase Inactivation and Glucokinase Activation in Control of Hepatocyte Glycogen Metabolism

Overview
Journal Diabetes
Specialty Endocrinology
Date 2005 Mar 1
PMID 15734835
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Glucokinase and phosphorylase both have a high control strength over hepatocyte glycogen metabolism and are potential therapeutic targets for type 2 diabetes. We tested whether combined phosphorylase inactivation and glucokinase activation is a more effective strategy for controlling hepatic glycogen metabolism than single-site targeting. Activation of glucokinase by enzyme overexpression combined with selective dephosphorylation of phosphorylase-a by an indole carboxamide that favors the T conformation of phosphorylase caused a greater stimulation of glycogen synthesis than the sum of either treatment alone. This result is explained by the complementary roles of elevated glucose-6-phosphate (G6P; a positive modulator) and depleted phosphorylase-a (a negative modulator) in activating glycogen synthase and also by synergistic inactivation of phosphorylase-a by glucokinase activation and the indole carboxamide. Inactivation of phosphorylase-a by the indole carboxamide was counteracted by 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside, which is metabolized to an AMP analog; this effect was reversed by G6P. Our findings provide further evidence for the inverse roles of G6P and AMP in regulating the activation state of hepatic phosphorylase. It is proposed that dual targeting of glucokinase and phosphorylase-a enables improved potency and efficacy in controlling hepatic glucose metabolism.

Citing Articles

Metformin lowers glucose 6-phosphate in hepatocytes by activation of glycolysis downstream of glucose phosphorylation.

Moonira T, Chachra S, Ford B, Marin S, Alshawi A, Adam-Primus N J Biol Chem. 2020; 295(10):3330-3346.

PMID: 31974165 PMC: 7062158. DOI: 10.1074/jbc.RA120.012533.


Glucose induces protein targeting to glycogen in hepatocytes by fructose 2,6-bisphosphate-mediated recruitment of MondoA to the promoter.

Petrie J, Al-Oanzi Z, Arden C, Tudhope S, Mann J, Kieswich J Mol Cell Biol. 2012; 33(4):725-38.

PMID: 23207906 PMC: 3571345. DOI: 10.1128/MCB.01576-12.


Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs.

Torres T, Sasaki N, Donahue E, Lacy B, Printz R, Cherrington A J Pharmacol Exp Ther. 2011; 337(3):610-20.

PMID: 21363927 PMC: 3207486. DOI: 10.1124/jpet.110.177899.


Hypermethylation of hepatic Gck promoter in ageing rats contributes to diabetogenic potential.

Jiang M, Fei J, Lan M, Lu Z, Liu M, Fan W Diabetologia. 2008; 51(8):1525-33.

PMID: 18496667 DOI: 10.1007/s00125-008-1034-8.


Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs.

Hampson L, Mackin P, Agius L Diabetologia. 2007; 50(8):1743-51.

PMID: 17579833 DOI: 10.1007/s00125-007-0696-y.